Study: NCT06735131

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy 5 Gy × 5 fractions, once a day
Description: 5 Gy × 5 fractions, once a day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy 8 Gy × 5 fractions, once a day
Description: 8 Gy × 5 fractions, once a day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy 8 Gy × 3 fractions, once every other day
Description: 8 Gy × 3 fractions, once every other day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy 10 Gy× 3 fractions, once every other day
Description: 10 Gy × 3 fractions, once every other day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotehrapy 0.5Gy twice-a-day × 2 days, repeat for 4 cycles (total 8Gy)
Description: 0.5 Gy twice-a-day × 2 days, on the first 2 days of the first 4 cycles of toripalimab and chemotherapy (total 8Gy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab (240 mg IV, d1, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab (240 mg IV, d1, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab (240 mg IV, d1, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab (240 mg IV, d1, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab (240 mg IV, d1, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy regimen selected by the investigator
Description: Regimens to be selected from: (1) Nab-paclitaxel (125 mg/m2 IV, days 1, 8, Q3W) (2) Gemcitabine (1000 mg/m² IV, days 1 and 8, Q3W) + carboplatin (AUC=2 IV, days 1 and 8, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy regimen selected by the investigator
Description: Regimens to be selected from: (1) Nab-paclitaxel (125 mg/m2 IV, days 1, 8, Q3W) (2) Gemcitabine (1000 mg/m² IV, days 1 and 8, Q3W) + carboplatin (AUC=2 IV, days 1 and 8, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy regimen selected by the investigator
Description: Regimens to be selected from: (1) Nab-paclitaxel (125 mg/m2 IV, days 1, 8, Q3W) (2) Gemcitabine (1000 mg/m² IV, days 1 and 8, Q3W) + carboplatin (AUC=2 IV, days 1 and 8, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy regimen selected by the investigator
Description: Regimens to be selected from: (1) Nab-paclitaxel (125 mg/m2 IV, days 1, 8, Q3W) (2) Gemcitabine (1000 mg/m² IV, days 1 and 8, Q3W) + carboplatin (AUC=2 IV, days 1 and 8, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy regimen selected by the investigator
Description: Regimens to be selected from: (1) Nab-paclitaxel (125 mg/m2 IV, days 1, 8, Q3W) (2) Gemcitabine (1000 mg/m² IV, days 1 and 8, Q3W) + carboplatin (AUC=2 IV, days 1 and 8, Q3W)